sorafenib has been researched along with voriconazole in 3 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (voriconazole) | Trials (voriconazole) | Recent Studies (post-2010) (voriconazole) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 4,390 | 219 | 2,678 |
Protein | Taxonomy | sorafenib (IC50) | voriconazole (IC50) |
---|---|---|---|
Cytochrome P450 2C9 | Homo sapiens (human) | 8.4 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 8.7 | |
Cholesterol 24-hydroxylase | Homo sapiens (human) | 0.0345 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Baker, SD; Chaudhry, AS; Finkelstein, D; Gibson, A; Inaba, H; Li, L; Roberts, JL; Rubnitz, JE; Schuetz, EG; Zimmerman, EI | 1 |
Freyer, CW; Mangan, JK | 1 |
1 review(s) available for sorafenib and voriconazole
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for sorafenib and voriconazole
Article | Year |
---|---|
Ontogeny and sorafenib metabolism.
Topics: Adolescent; Age Factors; Azoles; Child; Child, Preschool; Cytochrome P-450 CYP3A; Female; Humans; Infant; Infant, Newborn; Liver; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sex Factors; Sorafenib; Triazoles; Voriconazole; Young Adult | 2012 |
1 other study(ies) available for sorafenib and voriconazole
Article | Year |
---|---|
Dose-related periorbital edema following sorafenib in a patient with acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Edema; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Sorafenib; Voriconazole | 2019 |